USRM (US Stem Cell) Short-Term Debt: $8.27 Mil (As of Dec. 2022)


USRM US Stem Cell Inc USRM
12 GF Score
Price $0.00
View Full Analysis

What is US Stem Cell Short-Term Debt?

US Stem Cell USRM 12 Short-Term Debt is $8.27 Mil as of Dec. 2022. GuruFocus rates USRM with a GF Score™ of 12/100.

US Stem Cell's Short-Term Debt for the quarter that ended in Dec. 2022 was $8.27 Mil.

US Stem Cell's quarterly Short-Term Debt increased from Jun. 2022 ($7.86 Mil) to Sep. 2022 ($8.06 Mil) and increased from Sep. 2022 ($8.06 Mil) to Dec. 2022 ($8.27 Mil).

US Stem Cell's annual Short-Term Debt increased from Dec. 2020 ($6.73 Mil) to Dec. 2021 ($7.29 Mil) and increased from Dec. 2021 ($7.29 Mil) to Dec. 2022 ($8.27 Mil).

US Stem Cell Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

US Stem Cell Short-Term Debt Related Terms

US Stem Cell Short-Term Debt Historical Data

* Premium members only.

The historical data trend for US Stem Cell's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

US Stem Cell Short-Term Debt Chart

US Stem Cell Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.46 5.43 6.73 7.29 8.27

US Stem Cell Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.29 7.70 7.86 8.06 8.27
USRM
12GF Score
US Stem Cell Inc USRM
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $8.27 Mil mean?
US Stem Cell (USRM) has a Short-Term Debt of $8.27 Mil as of Dec. 2022.
Is US Stem Cell's Short-Term Debt too high?
US Stem Cell's current Short-Term Debt is $8.27 Mil. Overall, US Stem Cell has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does US Stem Cell's Short-Term Debt compare to NOVNQ and RGRX?
US Stem Cell's Short-Term Debt of $8.27 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. US Stem Cell's current Short-Term Debt is $8.27 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is US Stem Cell stock overvalued right now?
US Stem Cell (USRM) has a current Short-Term Debt of $8.27 Mil. The current Short-Term Debt is $8.27 Mil. US Stem Cell's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For US Stem Cell (USRM), the current Short-Term Debt is $8.27 Mil as of Dec. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

US Stem Cell Business Description

Address 1560 Sawgrass Corporate Parkway, 4th Floor, Sunrise, FL, USA, 33323
US Stem Cell Inc is a biotechnology company engaged in the discovery and development of autologous cell therapies for the treatment of chronic and acute heart damage. Its product includes MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. The company's discoveries include multiple cell therapies in various stages of development that repair damaged tissues throughout the body due to injury or disease so that patients may return to a normal lifestyle.
12GF Score

Get the complete analysis for USRM

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price